

Deletions at the *SOX10* Gene Locus Cause Waardenburg Syndrome Types 2 and 4

Nadege Bondurand, Florence Dastot-Le Moal, Laure Stanchina, Nathalie Collot, Viviane Baral, Sandrine Marlin, Tania Attie-Bitach, Irina Giurgea, Laurent Skopinski, William Reardon, Annick Toutain, Pierre Sarda, Anis Echaieb, Marilyn Lackmy-Port-Lis, Renaud Touraine, Jeanne Amiel, Michel Goossens, and Veronique Pingault

Waardenburg syndrome (WS) is an auditory-pigmentary disorder that exhibits varying combinations of sensorineural hearing loss and abnormal pigmentation of the hair and skin. Depending on additional symptoms, WS is classified into four subtypes, WS1–WS4. Absence of additional features characterizes WS2. The association of facial dysmorphic features defines WS1 and WS3, whereas the association with Hirschsprung disease (aganglionic megacolon) characterizes WS4, also called “Waardenburg-Hirschsprung disease.” Mutations within the genes *MITF* and *SNAI2* have been identified in WS2, whereas mutations of *EDN3*, *EDNRB*, and *SOX10* have been observed in patients with WS4. However, not all cases are explained at the molecular level, which raises the possibility that other genes are involved or that some mutations within the known genes are not detected by commonly used genotyping methods. We used a combination of semi-quantitative fluorescent multiplex polymerase chain reaction and fluorescent in situ hybridization to search for *SOX10* heterozygous deletions. We describe the first characterization of *SOX10* deletions in patients presenting with WS4. We also found *SOX10* deletions in WS2 cases, making *SOX10* a new gene of WS2. Interestingly, neurological phenotypes reminiscent of that observed in WS4 (PCWH syndrome [peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, WS, and Hirschsprung disease]) were observed in some WS2-affected patients with *SOX10* deletions. This study further characterizes the molecular complexity and the close relationship that links the different subtypes of WS.

During development, the pluripotent neural-crest cells migrate from the neural tube throughout the embryo along several pathways and give rise to different cell types, including glia and neurons of the peripheral nervous system, enteric neurons and glia, some of the craniofacial skeletal tissue, and melanocytes of the skin and inner ear.¹ Defects in neural-crest development are a significant cause of human disease. The term “neurocristopathies” collectively refers to these neural-crest disorders, one of which is Waardenburg syndrome (WS).^{2–4} The association of hearing loss and pigmentary abnormalities (e.g., heterochromia irides, white skin patches, and white forelock) characteristic of this syndrome results from an abnormal proliferation, survival, migration, or differentiation of neural-crest-derived melanocytes.³ Several subtypes of WS were defined on the basis of the presence of additional symptoms.

Type I WS (WS1 [MIM 193500]) refers to the first cases described by Waardenburg.⁵ Additional symptoms are dystopia canthorum and broad nasal root. Nearly all patients

present with heterozygous mutations of *PAX3* (encoding paired box gene 3 [PAX3], a member of the paired box family of transcription factors). Type III WS (WS3 [MIM 148820]), or Klein-Waardenburg syndrome, is an extreme presentation of type I WS, with hypoplasia of limb muscles, and is also caused by heterozygous or homozygous mutations of *PAX3*.^{3,6,7}

Type II WS (WS2 [MIM 193510]) is characterized by deafness and pigmentation defects without additional features. Heterozygous mutations in the *MITF* gene (encoding microphthalmia-associated transcription factor [MITF], a basic helix-loop-helix transcription factor) have been identified in ~15% of cases.^{3,8} Homozygous deletions of the *SNAI2* gene (encoding snail homolog 2, a C2H2-type zinc-finger transcription factor) have also been described in two patients.⁹ Therefore, 85% of WS2 cases are still unexplained at the molecular level.

Type IV WS (WS4 [MIM 277580]), also called “Shah-Waardenburg syndrome” or “Waardenburg-Hirschsprung

From INSERM U841, Institut Mondor de Recherche Biomedicale, Département de Génétique (N.B.; F.D.-L.M.; L. Stanchina; N.C.; V.B.; I.G.; M.G.; V.P.), Université Paris 12, Faculté de Médecine, IFR10 (N.B.; L. Stanchina; V.B.; I.G.; M.G.; V.P.), and Assistance Publique–Hôpitaux de Paris, Groupe Henri Mondor-Albert Chenevier, Service de Biochimie et Génétique (F.D.-L.M.; N.C.; I.G.; L. Skopinski; M.G.; V.P.), Créteil, France; Service de Génétique, Centre de Référence Surdités Génétiques, INSERM U587, Hôpital Armand Trousseau (S.M.), and INSERM U781, Université Paris 5-Descartes, Faculté de Médecine, Service de Génétique Médicale, Hôpital Necker (T.A.-B.; J.A.), Assistance Publique–Hôpitaux de Paris, Paris; Our Lady’s Hospital for Sick Children, Genetics, Dublin (W.R.); Centre Hospitalo-Universitaire, Service de Génétique, Tours, France (A.T.); Centre Hospitalo-Universitaire, Service de Génétique, Montpellier, France (P.S.); Service de Chirurgie Infantile, Hôpital Pierre Zobda Quitman, Centre Hospitalier Universitaire Fort de France, Fort de France, France (A.E.); Service de Pédiatrie, Centre Hospitalier Universitaire de Pointe à Pitre, Pointe à Pitre, France (M.L.-P.-L.); and Centre Hospitalier Universitaire–Hôpital Nord, Service de Génétique, Saint Etienne, France (R.T.)

Received June 18, 2007; accepted for publication August 1, 2007; electronically published October 22, 2007.

Address for correspondence and reprints: Dr. Nadège Bondurand, INSERM U841, Institut Mondor de Recherche Biomedicale, Département de Génétique, Equipe 11, Hôpital Henri Mondor, 51 Avenue du Maréchal de Lattre de Tassigny, 94010, Créteil, France. E-mail: nadege.bondurand@creteil.inserm.fr
Am. J. Hum. Genet. 2007;81:1169–1185. © 2007 by The American Society of Human Genetics. All rights reserved. 0002-9297/2007/8106-0006\$15.00
 DOI: 10.1086/522090

disease," combines pigmentation defects, deafness, and Hirschsprung disease.¹⁰ Mutations in *EDNRB*, which encodes the endothelin B receptor (a G-protein-coupled transmembrane receptor), and *EDN3*, which encodes its ligand, endothelin-3, have been described. Homozygous (most frequently) or heterozygous mutations are found in probands with WS4, whereas heterozygous family members occasionally present with some of the features.^{4,11–17}

Dominant mutations of *SOX10* have also been identified in WS4.¹⁸ *SOX10* is a key transcription factor of neural-crest development. It is crucial for the survival and maintenance of pluripotency of migrating neural-crest progenitors^{19,20} and also influences fate decisions and differentiation at later stages.^{21–25} *SOX10* belongs to the SOX family of transcription factors and is closely related to *SOX8* and *SOX9*, the latter of which is involved in camptomic dysplasia.^{21,23,25–27} All SOX proteins contain a DNA-binding motif known as the high-mobility group (HMG) domain. In addition, *SOX10*, like *SOX8* and *SOX9*, contains a transactivation domain located in the C-terminal part of the protein and a dimerization domain immediately preceding the HMG domain.^{21,22,28,29} Functional studies revealed the importance of these domains for monomeric or dimeric DNA binding and transactivation of natural target genes.^{21,22} Among them are genes/factors crucial for the specification and differentiation of melanocytes or enteric nervous-system development, such as *MITF/Mitf*, *TRYP2/Dct* (encoding dopachrome tautomerase), tyrosinase, *EDNRB*, and the *RET* protooncogene.^{30–41} *SOX10* targets also include genes important for glia development and identity, such as *MPZ* (encoding myelin protein zero [P0]), *MBP* (encoding myelin basic protein), and *GJB1* (encoding the gap-junction protein connexin 32).^{29,42–46}

The *SOX10* mutations characterized so far are mostly truncating mutations—that is, nonsense and frameshift mutations and one splice mutation—which most often remove all or part of the transactivation domain.^{18,47–58} An insertion of 2 aa and an amino acid substitution in the HMG domain, as well as two mutations of the stop codon supposed to give rise to elongated *SOX10* protein, have also been described.^{18,48,49,53} Unexpectedly, some of the patients with *SOX10* mutations present with chronic intestinal pseudo-obstruction instead of Hirschsprung disease^{51,55} and/or with neurological features, either peripheral demyelinating neuropathy or central neuropathy or both, which leads to a syndrome called "PCWH" (peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, WS, and Hirschsprung disease).⁵⁷ This more severe disease is mostly caused by mutations in the last coding exon of *SOX10* and has been proposed to occur when the mutant mRNAs escape the nonsense-mediated mRNA decay (NMD) pathway.⁵⁷

However, some WS4 cases remain unexplained at the molecular level, which suggests that other genes may be involved or that some mutations within the known genes are not detected by the methods commonly used for ge-

notyping. Therefore, we used semiquantitative fluorescent multiplex PCR (QMF-PCR) to search for heterozygous *SOX10* deletions. Here, we describe the first characterization of *SOX10* deletions in patients presenting with WS4. In light of the phenotypic variability observed among patients with *SOX10* point mutations, we also searched for *SOX10* deletions in unexplained cases of WS2 and found several, making *SOX10* a new gene of WS2.

Subjects and Methods

Subjects

We investigated a total of 30 patients presenting with the classic form of WS4 or PCWH; 29 were found to be negative for *EDN3*, *EDNRB*, and *SOX10* point mutations, and 1 was found to be hemizygous for a *SOX10* point variation within the course of this work. Our study also included 30 WS2-affected patients without *MITF* mutations. Clinical information and DNA samples were obtained with informed consent in accordance with French law for genetic testing. The main clinical findings in patients presenting with *SOX10* gene deletions are summarized in table 1. Detailed clinical descriptions of the patients presenting with *SOX10* gene deletions are as follows.

Patient 1, a 1-year-old boy, was born at term to unrelated parents after unremarkable pregnancy and delivery. At age 48 h, he presented with clinical signs of meconium plug syndrome caused by short-segment Hirschsprung disease. Bilateral absence of responses to brain stem auditory-evoked potential strongly suggested bilateral deafness. He also had hair and skin hypopigmentation and bilateral cryptorchidism.

Patient 2, a 13-year-old boy, was born at term to unrelated parents after a pregnancy complicated by gestational diabetes. He has two healthy sisters. He had delayed psychomotor development, hair and skin hypopigmentation, sapphire blue eyes, and short-segment Hirschsprung disease that required a surgical procedure at age 15 mo. Nine months later, he had implantation of a unilateral cochlear device for profound bilateral congenital deafness. In spite of good perceptual results, he had speech and sign-language impairment because of dyspraxia. He had mild mental retardation, anosmia, hypermetropia, and dental-enamel abnormalities.

Patient 3, a 36-year-old man, was born at term to unrelated parents after unremarkable pregnancy and delivery. In the neonatal period, he had axial hypotonia and delayed psychomotor development; he could hold his head up at age 1 year, sit alone at age 3 years, and walk at age 4–5 years. He had hair and skin hypopigmentation, sapphire blue eyes, short-segment Hirschsprung disease, and profound bilateral congenital deafness, for which he had implantation of a unilateral cochlear device at age 32 years. Temporal bone CT scan revealed a bilateral vestibular malformation and hypoplasia of the external and posterior semicircular canals. He also presented with anosmia, bilateral cryptorchidism, hypogonadotropic hypogonadism, and bone-age and pubertal growth delay. He now has mild mental retardation with marked abstraction difficulties.

Patient 4, a 9-year-old boy, was born at term to unrelated parents after unremarkable pregnancy and delivery. He began to walk at age 21 mo. A bilateral sensorineural hearing impairment was discovered at age 6 mo and progressed to profound deafness. A cochlear implantation was performed with success, in terms of his comprehension and language skills. Temporal bone CT scan

Table 1. Summary of Clinical Findings

Patient	Sex	Age	Phenotype ^a						Molecular Defect		
			WS Type	Deafness	Pigmentation Anomalies	HSCR	MR	Other(s)	Inheritance	Deletion Nomenclature ^b	Deletion Size
1	M	1 year	WS4	Bilateral	Hair and skin hypopig.	Short	No	Bilateral cryptorchidism	De novo	c.697-740_1085del ins CCT	1,128 bp del and 3-bp ins
2	M	13 years	PCWH	Profound bilateral	Hair and skin hypopig., sapphire blue eyes	Short	Mild	Anosmia, hypermetropia, dental-enamel abnormalities	De novo	g.(17,738,296_17,740,110)_(17,794,727_17,801,789) del	56-68 kb
3	M	36 years	PCWH	Profound bilateral	Hair and skin hypopig., sapphire blue eyes	Short	Mild	Anosmia, cryptorchidism, hypogonadism	De novo	g.(17,712,505_17,716,229)_(17,929,647_17,933,832) del	213-222 kb
4 ^c	M	9 years	WS2	Profound bilateral	Skin, irides, and retinal hypopig.	No	No	...	Maternal (mosaicism)	c.219_428+43del	253 bp
5	M	8 years	WS2	Profound bilateral	Skin depigmentation, hypoplastic irides	No	No	...	Maternal	c.429-1112_697+396del	1,777 bp
6	M	8 years	WS2	Profound bilateral	White frontal forelock, heterochromia irides	No	No	...	De novo	g.(16,173,196_16,489,188)_(17,790,847_17,791,697) del	1.3-1.6 Mb
7	M	23 years	WS2	Bilateral	Skin hypopig., sapphire blue eyes	No	Severe	Short stature, pectus excavatum, autism	De novo	g.(17,357,039_17,432,022)_(18,006,412_18,254,748) del	574-898 kb
8	F	19 mo	WS2	Yes	Skin hypopig., white forelock	No	Delayed	Thumb duplication, congenital heart disease	De novo	g.(Z83846_Z69042)_(18,938,054_19,010,379) del	5.5-6.1 Mb

^a HSCR = Hirschsprung disease; MR = mental retardation; hypopig. = hypopigmentation.

^b The deletions are described in relation to the human genome reference sequence National Center for Biotechnology Information (NCBI) build 36.2 accession number NT_011520.11.

^c The brother of patient 4 presented with similar clinical symptoms.

Table 2. QMF-PCR Primer Sequences

Primer	Primer Sequence (5'→3')		Reaction Mix	PCR Product Size (bp)	Gene Position	GenBank Accession Number
	Forward	Reverse				
Reference:						
<i>DSCR1</i>	GCGACGAGGACGCATTCCAA	GTCCTGTGCGATCACCACA	1 and 2	238	<i>DSCR1</i> exon 4	NC_000021.7
<i>F9</i>	AAATGATGCTGTTACTGTCTA	GAAGTTTCAGATACAGATTTTC	1 and 2	214	<i>F9</i> exon 5	NC_000023.9
<i>SOX10</i> :						
P5	GGCCAGGCGAGCTGGGCAAGGTC	GAATCCACCCGAAGCTAGAG	1	341	<i>SOX10</i> exon 3	NC_000022.9
P6	GGAGTGTCTGGCATTACAG	CTTGCCCAACCTCAGCTCT	1	366	<i>SOX10</i> exon 4	NC_000022.9
P7	GGAAGTTCACGTGCGCCAC	GCGGCAGTACTGTCCAAC	1	286	<i>SOX10</i> exon 5	NC_000022.9
P8	CCACTACTACCGACCAGCC	GGGTGTTGGCGACAGGCG	1	326	<i>SOX10</i> exon 5	NC_000022.9
External markers:						
P9	GATGACGTTTCTAGGTGG	TGTTCTAAGGATCTGTAGG	1	309	<i>POLR2F</i> exon 4	NC_000022.9
P1	GAGGAGGGAGTTTGGGTGGTGG	GCACAGGATGGGACGGTTGAGA	2	310	-54694/-55003	NC_000022.9
P2	TGGGAACAATGTCAACGTCG	CAGAAGGCCTCCTCAATGA	2	330	-32490/-32819	NC_000022.9
P3	TACCAGGGCGGGCTCCTGTA	GCCCTGTTCCTCCAGACTCCC	2	363	-14793/-15155	NC_000022.9
P4	ACACGACGGCAGATGCTCTGT	CCTCGAGCCAGTGAATTA	2	335	-2116/-2450	NC_000022.9

NOTE.—GenBank accession numbers, positions, sequences, and expected PCR product sizes are given for primers P1–P9. Positions of primers P1–P4 are given with the A of the *SOX10* ATG numbered as 1. NCBI build 36.2 was used.

revealed a symmetrical bilateral vestibular malformation with dilatation of the vestibule, hypoplasia, and dilatation of the external and posterior semicircular canals. He presented with hypopigmentation of the skin, irides, and retina. He had no history of constipation, and his neurological development was normal. His brother presented with similar clinical symptoms. No other cases of hearing defect or pigmentation anomalies were observed in the family.

Patient 5, an 8-year-old boy, was born at term to unrelated parents after unremarkable pregnancy and delivery. He began to walk at age 20 mo. A profound bilateral sensorineural hearing impairment was diagnosed at age 5 mo. Temporal bone CT scan did not reveal any malformation of the inner ears. He presented with skin depigmentation and hypoplastic irides. He had no history of constipation, and his neurological development was normal. His mother presented with a bilateral severe sensorineural prelingual hearing impairment. She was born with a frontal white forelock and heterochromia (i.e., one green iris and one hypoplastic iris).

Patient 6, an 8-year-old boy, is the third child of a nonconsanguineous couple from the French Caribbean islands. At age 9 mo, a severe bilateral sensorineural hearing impairment was diagnosed and progressed to bilateral profound deafness by age 8 years. He presented a white frontal forelock at birth and heterochromia irides (i.e., one black and one hypoplastic) but has no skin depigmentation. He began walking at age 17 mo and has no history of severe constipation or neurological anomaly.

Patient 7, a 23-year-old man, was born at term to unrelated parents after unremarkable pregnancy and delivery. He presented with a white frontal forelock (now disappeared), skin hypopigmentation, sapphire blue eyes, pectus excavatum, and statural growth on the 3rd percentile. He has no constipation problems. In addition, this patient has severe autism and developmental delay (he started to walk at age 3 years, is not toilet trained, and has little autonomy). Brain CT scan was normal. Bilateral sensorineural deafness was diagnosed at age 9 mo, and he had a cochlear implant until age 13 years. However, because of severe behavioral problems, hearing loss has not been evaluated since age 13 years.

Patient 8 was born at term to unrelated parents after unre-

markable pregnancy and delivery. She presented with severe congenital heart disease associating double-outlet right ventricle, transposition of the great arteries, pulmonary atresia, patent ductus arteriosus, ventricular septal defect, and atrial septal defect. A white forelock and a duplication of the thumb on the left side were noted. At age 10 mo, she presented obvious evidence of deafness, medial flare of the eyebrows, strabismus, and general hypotonia. Brain magnetic resonance imaging scan at age 14 mo showed delayed myelination. Specific evaluation of the skin on Wood's lamp revealed multiple hypopigmented areas. She had no history of constipation. Heart surgery had been partially successful, but episodes of unexplained bradycardia and peripheral cyanosis were observed, and the patient died at age 19 mo.

QMF-PCR

QMF-PCR has been shown to be a sensitive method for the detection of gene-dosage anomalies and has been successfully used in our laboratory to characterize deletions and duplications within several genes.^{59,60} We adapted the protocol described elsewhere,^{61,59} to screen for *SOX10* gene deletions. In brief, the three coding exons of *SOX10*, exon 4 of *POLR2F*, and four regions located 5' of *SOX10* were amplified in two multiplex reactions. The beginning of exon 3 and the middle of the exon 5 coding sequences are not covered by the amplicons; however, a deletion restricted to one of these regions would have been found during the point-mutation screening. Noncoding regions of *SOX10* were not studied. GenBank accession numbers, positions, sequences of the primers, and PCR product sizes are shown in table 2. In each set, two controls were used: *DSCR1*, located on chromosome 21, and *F9*, located on chromosome X (see reference genes in table 2). The reverse primers were labeled with the fluorescent phosphoramidite 6-FAM dye. Amplifications were performed in duplicates in 25- μ l reactions with use of the QIAGEN Multiplex PCR kit (Qiagen), with 75 ng of genomic DNA, a mix of primers (concentration range 0.1–1 μ M), and 5% dimethyl sulfoxide (DMSO). The reaction started with an initial denaturation for 15 min at 95°C, followed by 22 cycles at 95°C for 30 s, at 55°C (multiplex reaction mix 1) or 58°C (multiplex reaction mix 2) for 30 s, and at 72°C for 45 s with an increment of 3 s per cycle, and

a final extension for 10 min at 72°C. Then, 3 μ l of the purified PCR products were processed as described elsewhere.⁵⁹ Two control DNA samples (male and female) were included in each experiment. Results were analyzed by superimposing fluorescent profiles of tested patients and controls and by calculating dosage quotient (DQ).⁵⁹ DQ values <0.6 were considered as indicating potential deletions. Table 3 summarizes examples of DQ values obtained.

Molecular Characterization of Rearrangements

When QMF-PCR revealed a short-size deletion (only one exon removed), the genomic region encompassing the deletion breakpoint was amplified either by classic or long-range PCR with the use of Dynazyme Ext DNA polymerase (Ozyme) or the Expand Long Template PCR system (Roche Diagnosis), respectively. The resulting PCR fragments were cloned into the TOPO-TA cloning kit dual promoter or the TOPO-XL PCR cloning kit (Invitrogen) and were sequenced. Bioinformatics analysis was performed to predict the functional consequences of intragenic deletions, with the use of Netgene2 (neural-network predictions of splice sites in humans) and HMMgene (gene-structure prediction) software.

In the case of whole *SOX10* gene deletions, FISH was used to confirm the QMF-PCR results. Molecular cytogenetic studies were performed on chromosomes prepared from cultured fibroblasts (patient 8) or peripheral blood cells. Metaphase chromosomes were obtained according to standard techniques. FISH was performed as described elsewhere.⁶² PAC and BAC clones used in FISH experiments were provided by the BACPAC Resources Center (Children's Hospital Oakland, Oakland, CA) or by The Wellcome Trust Sanger Institute (Cambridge, United Kingdom). Clones localized on chromosome 22q12-q13.2 (CTA-415G2, LL22NCO1-95B1, RP1-288L1, CTA-714B7, RP1-41P2, CTA-390B3, RP5-1177I5, RP1-37E16, RP3-466N1, RP5-1014D13, RP5-1039K5, CTA-228A9, CTA-447C4, RP1-506, RP3-434P1, RP1-319F24, RP3-508I1S, RP3-327516, CTA-150C2, RP4, 742C19, and LL22NC03-10C3) were directly labeled with Cy3. The control probes (RP1-41P2 and RP1127L4) were directly labeled with fluorescein isothiocyanate, and chromosomes were counterstained with 4',6-diamidino-2-phenylindole (DAPI). The specific signal intensity and its sub-localization along the chromosome axis were analyzed using a Leica fluorescence microscope equipped with the Visilog-6 program (Noesis). On the basis of FISH results, additional QMF-PCR

primers were designed to delineate the extent of deletions. Positions and sequences of these additional primers are reported in table 4.

Chromosome Segregation Analysis

Seven chromosome 22 microsatellites (*D22S420*, *D22S539*, *D22S315*, *D22S280*, *D22S283*, *D22S423*, and *D22S274*) were analyzed in patient 3 and his parents, with use of the linkage mapping set (Applied Biosystems) in accordance with the manufacturer's instructions.

SOX10 Point-Mutation Screening in Patients with WS2

In the absence of a full description of the 5' UTR noncoding exon(s) of *SOX10*, we used, for convenience, the exon-numbering system used elsewhere—that is, noncoding exons 1 and 2, the ATG codon in exon 3, and the stop codon in exon 5.¹⁸ Three sets of primers were used to amplify the *SOX10* gene fragments covering coding exons 3–5 and intron-exon boundaries (first set: exon 3, forward 5'-ACCCACCTAGAGTCTGGCATG-3' and reverse 5'-CTCGGCTACCCCTGAATCCAC-3', 733-bp PCR product; second set: exon 4, forward 5'-CCACAAATCATAGGGCACAG-3' and reverse 5'-TAGAGTCCAGGGTCTCATTG-3', 523-bp PCR product; third set: exon 5, forward 5'-CCTGCCTAACCTGCTTCC-3' and reverse 5'-ACCTCCTTCTCCTCTGTCCA-3', 997-bp PCR product). The PCR covering the exon 3 region contained 10% DMSO. Resulting PCR products were sequenced using a 16-capillary ABI Prism sequencer and the Terminator Cycle Sequencing kit. Additional internal sequencing primers were used for exon 3 (forward 5'-GCGAGCTGGCAAGGTCAAG-3' and reverse 5'-TCGCC-GTCTGCTGCTCCTT-3') and for exon 5 (forward 5'-GGATGCC-AAAGCCAGGTGA-3' and reverse 5'-GTAGGCGATCTGTGAGG-TGG-3').

Plasmids, Cell Culture, Transfection, and Reporter Assays

The pECE-SOX10, pECE-SOX10-E189X, pECE-SOX10-Y313X, pECE-SOX10-482ins6, pECE-PAX3, pECE-EGR2, pGL3-MITFdel1718, and pGL3-Cx32 vectors were described elsewhere.^{30,43} The p.Val92Leu mutation (named "V92L" for convenience) was introduced within the pECE-SOX10 construct by site-directed mutagenesis with use of the QuikChange Mutagenesis Kit (Strata-

Table 3. DQ Values from QMF-PCR Performed with Mix 1

DNA Sample	<i>SOX10</i> 5' Region S4 (P4)	<i>SOX10</i>				<i>POLR2F</i> Exon 4 (P9)
		Exon 3 (P5)	Exon 4 (P6)	Exon 5 (P7)	Exon 5 (P8)	
Subject 1	1.07	1.02	1.12	1.02	1.02	1.00
Subject 2	1.02	1.08	1.03	.97	.93	.94
Patient 1	1.00	1.02	.96	.47	1.10	.86
Patient 2	.46	.50	.46	.51	.49	.45
Patient 3	.47	.47	.48	.51	.51	.51
Patient 4	1.20	.58	.90	1.17	1.20	.83
Patient 5	.90	1.10	.56	1.08	.96	.99
Patient 6	.52	.54	.48	.52	.56	.43
Patient 7	.56	.56	.45	.54	.57	.48
Patient 8	.51	.46	.53	.50	.49	.50

NOTE.—The analysis is based on the comparison of the peak height from the tested DNA (two patients without deletion, called subjects 1 and 2, and patients 1–8) to control DNA samples. The copy-number change for each amplicon was calculated using the peak value normalized to the peak value of *DSCR1* exon 4. DQ values <0.6 are indicated in bold.

Table 4. Additional QMF-PCR Primers, Ordered Centromeric to Telomeric

Gene Position	Primer Sequence (5'→3')	
	Forward	Reverse
<i>FBX07</i> exon 1	CGCCTCAGCTACCCCTCAGC	CCGGCCCCAGCGTACCTGTA
<i>TIMP3</i> exon 1	CTGGAGGGTAGCAGTTAGC	GATCGTTCAGATCCTTATAG
<i>ISX</i> exon 1	GATCAACAACCTGTCAGCTCC	CCTGCAGGTGGAGGCTGAGG
<i>TOM1</i> exon 1	CGGTAGCAGCAATGGACTTT	TCCTTACTACTGGCTGTCA
<i>APOL3</i> exon 4	TTCAGGCATCTTCTTGAC	AAGTACTAACACTCAGCTC
<i>MYH9</i> intron 1	AGGCGGTGTCTCCACCGGG	GAGTGATTGTCTCAAAGGC
<i>CACNG2</i> exon 1	CACACTCTCCGAGAACCAG	CAAGTACCTTAGGCAGCA
<i>LGALS2</i> exon 4	GAGAGCCTGGCTGGACACA	GAAAGAGGACATGTTGAACC
<i>SH3BP1</i> exon 10	TGTGACGGATGATTTAGAT	ATGCCCTCAGAAAGCAGCAT
<i>TRIOBP</i> exon 1	GGTGAAATCTCAGCTCTC	GTATCTTACTGTGCAAGGG
<i>MICALL1</i> exon 8	CCCATGGATCAGCTGGTGC	TAGGGGTGATGCCGTACCAG
<i>MICALL1</i> intron 9	TATAATGTACATGCTGCTGT	GTAAGGAGCCAGGCAATCC
<i>MICALL1</i> exons 11–12	GACATCCATGGAGAGATGGA	GAGCTCGGACTCTCGCCGCA
<i>MICALL1</i> exon 16	GGCAGCGGTGATTCAGCCCT	ACTGAGATCCAAGGGCGCCT
<i>C22ORF23</i> exon 4	GATGCTTTGCCCTACAGTG	GCTGAGGCTCAAGAGCATTG
<i>C22ORF23</i> exon 3	CAGAGGGCAGAAATTTTATT	CATGATGCCATGATGTGGC
<i>POLR2F</i> exon 1	CAGTCAGCGCATGCGCACTT	CAGACATTGCCCTAGACGC
P2_3-4 -20540/-20829	CAGAGGTAATCAAGTTAGCC	GTATTAGGATGGGTCTGATGG
P2_3-3 -21390/-21739	CACCTGGCCAGGATGAGCTT	CCACAGTGAGCACTCAGGAA
P2_3-2 -23920/-24166	TTGTAAGCAACAGAGGAGC	CCTCCGCAAAAGACTTGCTG
P2_3-1 -31482/-31759	CCAAAAGCAGAAATCTGGGA	GGCCTGAGGCTCCAGCTGAG
<i>PLA2G6</i> exon 7	GATGGGATGGGAGGAGTCT	CCGTGGGTCAGCAGCACTAT
<i>PLA2G6</i> exon 4	GGCGGGAATGCTTTGAGCT	CACCTGGACAGCATAATGG
<i>PLA2G6</i> intron 2	GGCTTCAGGAGGGCAGAGCA	CCAGGGCTTTAACATACCA
<i>PLA2G6</i> exon 2	CCTTCAGTGGCGTACCAAC	GGTCCAAGAGTACAGTCTCC
<i>C22ORF5</i> exon 9	CTCTAGACCTGGGGCTCCG	ATGCAGGCTCTGCCACGAG
<i>KDELR3</i> exon 1	TGGACCATGAACGTGTTCCG	ATCATCTCGAGGGGCTCTCC
<i>DDX17</i> exon 1	TTGTGCAGTCGCTGGGAAGG	GATAGAGATCTGGGAGCGGG
<i>CBX7</i> intron 1	TCCTACCCATCTGCCTTCT	CCTGGAGCCTCCAAAGGGC
<i>PDGFB</i> exon 7	AGCCTGTGGCTGGAGTGGC	GTGGGAGCTCAGATCCCACC

NOTE.—The positions of primers P2_3-1 to P2_3-4, located between P2 and P3 (see table 2), are given with the A of the *SOX10* ATG numbered as 1. NCBI build 36.2 was used. The GenBank accession number for all primers is NC_000022.9.

gene). Luciferase assays and immunofluorescence experiments were performed 24 h after transfection of HeLa cells, as described elsewhere.^{30,43,63} The *SOX10* antibody used for immunofluorescence experiments was described elsewhere.⁶⁴ The P0 construct was kindly provided by M. Wegner.²⁹

Results

Identification of *SOX10* Deletions in Patients Presenting with WS4 or PCWH

In our experience, ~20%–40% of affected individuals with the WS4 or PCWH phenotypes have no mutations within *SOX10*, *EDN3*, or *EDNRB* identifiable by conventional genetic analysis with the use of DNA sequencing of PCR-amplified gene segments. Since this technique does not detect heterozygous deletions, we decided to search for *SOX10* deletions or rearrangements by QMF-PCR. Our study included 29 patients presenting with the classic form of WS4 or PCWH, previously found to be negative for *SOX10*, *EDN3*, and *EDNRB* point mutations. We first analyzed the three coding exons of *SOX10*, part of the *POLR2F* downstream gene, and sequences located up to 50 kb upstream of *SOX10* (S1–S4) (see fig. 1A). One

of them, S1, was described elsewhere as a *SOX10* enhancer⁶⁵ (see table 2 for sequences of primers P1–P9).

We identified two heterozygous deletions (patients 1 and 2; see the “Subjects” section and table 1 for clinical descriptions). The first, found in a patient presenting with a classic WS4 phenotype, removes part of exon 5 (fig. 1A, patient 1). PCR amplification with the use of primers located in intron 4 and exon 5 and cloning and sequencing of the resulting products revealed a complex rearrangement combining a 1,128-bp deletion, encompassing 740 bp of intron 4 and 388 bp of exon 5, and a 3-bp insertion (fig. 1B). The other deletion, found in a patient with PCWH, includes the whole *SOX10* gene, *POLR2F*, and the upstream S4 sequence (fig. 1A, patient 2). FISH analysis with use of a BAC encompassing the whole region (clone RP5-1039K5) (fig. 1A) confirmed the QMF-PCR results. Indeed, we observed a significantly decreased signal on one of the chromosomes 22 in all the metaphases (fig. 1C, patient 2), showing that the deletion removes only part of the RP5-1039K5 probe (S1–S3 are not deleted) (see fig. 1A). In each of the two cases, the analysis of parent DNA




Figure 1. *SOX10* deletions in patients presenting with the classic form of WS4 or PCWH. **A**, Schematic representation of the three deletions identified by QMF-PCR. The scheme on the top indicates the *SOX10* gene structure (an approximate scale is shown on the right). *SOX10* coding sequence (exons 3–5) is indicated with black boxes, and noncoding exonic sequence is indicated with white boxes. Arrowheads indicate the position of the segments analyzed by QMF-PCR (P1–P9; see table 2 for corresponding primer sequences). They include the downstream adjacent *POLR2F* gene (gray box) and four short regions located up to 50 kb upstream of *SOX10*, indicated by dark lines and labeled S1–S4. QMF-PCR results for patients 1–3 are indicated: + = not deleted; – = deleted. The phenotypes are indicated on the left. **B**, Schematic representation (top) and electropherogram (bottom) of the deletion breakpoint region of patient 1. The size of the deletion and the nucleotidic localization of the breakpoint are indicated on the diagram. The 3 inserted nt are boxed. **C**, Hybridization pattern of patients 2 and 3 with use of BAC clone RP5-1039K5 encompassing the *SOX10* locus (indicated at the top of panel A). The BAC clone RP5-1039K5 is shown in red, and the control probe (RP1-41P2) is shown in green. The normal chromosome 22 is indicated by an arrow, and the deleted chromosome 22 is indicated by an arrowhead.

by QMF-PCR revealed the de novo occurrence of the deletion (table 1).

Detection of a SOX10 Deletion in a Patient with PCWH with p.Val92Leu Variation

Sequencing of the *SOX10* coding exons and intron-exon boundaries in newly recruited patients led us to identify a new point mutation (nucleotide substitution c. 274G→C in exon 3) that predicts the replacement of a valine by a leucine at codon 92 (p.Val92Leu) in a patient presenting with PCWH (patient 3) (see the “Subjects” section and table 1 for clinical description). This amino acid substitution affects a residue located within a region directly preceding the HMG domain that is well conserved not only between *SOX10* proteins across evolution but also among the SOX E members, *SOX8* and *SOX9* (fig. 2A).²⁸ Surprisingly, this variation was observed at the homozygous state and therefore contrasts with the heterozygous state of all the mutations identified to date. The parents were not consanguineous and did not present any feature

of the disease, except for early graying hair in the mother. We found the mutation at the heterozygous state in the father’s DNA only. The analysis of seven chromosome 22 microsatellites excluded a chromosome segregation abnormality and the possibility of a chromosome 22 paternal isodisomy (data not shown).

To explain these data, we searched for a deletion or rearrangement of *SOX10* that would result in a hemizygous p.Val92Leu mutation. QMF-PCR experiments indeed unraveled a deletion that removes the whole *SOX10* gene, along with the upstream and downstream sequences tested (fig. 1A, patient 3). FISH analysis with use of the BAC clone RP5-1039K5 confirmed the presence of a deletion encompassing the whole region (fig. 1C, patient 3, showing presence of only one signal on the normal chromosome 22). Analysis of parent samples established the de novo occurrence of the deletion (table 1).

These results suggested that the phenotype of patient 3 is related to this large deletion, but we could not exclude the possibility that the p.Val92Leu variation contributes




Figure 2. Functional consequences of the p.Val92Leu (V92L) mutation. *A*, Amino acid sequence comparison of the region immediately preceding the HMG domain of *SOX10* proteins across evolution and of SOX subgroup E proteins (human sequences). Gaps are indicated by blanks. The first part of the HMG domain is boxed, and the amino acid substitution V92L from patient 3 is indicated by an arrow. *SOX10* sequence reference numbers: human (accession number NP_008872.1), mouse (XP_128139.4), chicken (NP_990123.1), fugu (NP_001072112.1), zebrafish (NP_571950.1), human *SOX8* (NP_055402.2), and human *SOX9* (NP_000337.1). *B*, Subcellular localization of wild-type *SOX10* and p.Val92Leu mutant. HeLa cells were transfected with pECE-*SOX10* (WT) or mutant (V92L) constructs for 24 h, were fixed, and were immunostained for *SOX10*. Cultures were counterstained with DAPI. *C* and *D*, Transactivation capacities of *SOX10* proteins. The *MITF* promoter (pMITF) (*C*) or the *GJB1* (pCx32) promoter (*D*) luciferase reporters were transfected in HeLa cells in combination with wild-type (WT) or mutant *SOX10* proteins (V92L, E189X, 482ins6, and Y313X), and/or PAX3 (*C*) or EGR2 (*D*). Reporter-gene activations are presented as fold induction relative to the empty expression vector (pECE). Results represent the mean ± SEM from six experiments, each performed in duplicate. Insets in *C* and *D* show a schematic representation of relative localization of *SOX10* (white boxes), PAX3 (striped circles) or EGR2 (striped triangles) binding sites on *MITF* or *GJB1* (Cx32) promoters.

to the phenotype. To test this possibility, we introduced the mutation into the *SOX10* cDNA and analyzed its functional consequences in vitro. Immunofluorescence experiments on HeLa cells transiently transfected with wild-type or p.Val92Leu constructs revealed correct nuclear localization of the mutant protein (fig. 2B).

The region affected by the mutation was previously implicated in DNA-dependent dimerization, both in *SOX10* and *SOX9*.^{29,42,45,66} Moreover, a *SOX9* mutation located in the same region (p.Ala76Glu) was shown to selectively abrogate DNA-dependent dimerization and to thus interfere with promoter activation via natural target sites that require binding of *SOX9* as dimers.⁶⁶ We therefore analyzed the transactivation potential of the p.Val92Leu mutant on two promoters previously shown to contain monomeric or dimeric *SOX10* binding sites—*MITF* and *Cx32*, respectively. Indeed, *SOX10*, in synergy with *PAX3*, regulates *MITF* expression by directly binding to its promoter as monomers.^{30,33} *SOX10*, on the other hand, regulates *GJB1* (encoding connexin 32 [Cx32]) expression by directly binding to its promoter on a dimeric configuration and in synergy with its cofactor *EGR2*.^{43,67} (insets in fig. 2C and 2D). Cotransfection of either promoter with wild-type or p.Val92Leu *SOX10* mutant and/or *SOX10* cofactors (*PAX3* and *EGR2*) revealed that normal and mutant *SOX10* have similar transactivation capacities on these promoters, alone or in synergy with the cofactors (fig. 2C and 2D). In contrast, three previously identified *SOX10* mutations (p.Glu189X, c.482ins6, and p.Tyr313X, named “E189X,” “482ins6,” and “Y313X,” respectively, in fig. 2C and 2D) failed to transactivate these reporter constructs, as described elsewhere.^{30,43,68} We also performed similar experiments, using another *SOX10*-responsive promoter known to contain *SOX10* dimeric binding sites, *P0*, and found no difference between wild-type and p.Val92Leu mutant transactivation capacities (data not shown). Therefore, the p.Val92Leu variation does not seem to affect *SOX10* function, at least in vitro, which argues in favor of the deletion as the cause of the phenotype observed in this patient.

Molecular Characterization of Large Deletions in Patients with PCWH

To define the boundaries of the deletions encompassing the *SOX10* gene found in patients 2 and 3, we extended our analysis to adjacent regions, using two complementary strategies: FISH and QMF-PCR. In the case of patient 2, we chose additional sets of QMF-PCR primers localized between upstream S3 and S4 sequences, which allowed us to map the telomeric border of the deletion to a region located 24–31 kb upstream of the *SOX10* start codon (fig. 3B, patient 2). In parallel, FISH experiments with the probe RP5-1014D13 (covering regions proximal to *POLR2F*, including *MICAL-L1*) (see fig. 3) showed a distinct signal on both chromosomes 22, positioning the centromeric border of the deletion between *POLR2F* and *MICAL-L1* (fig.

3A). We chose additional sets of QMF-PCR primers within the genes located in the region and localized the end of the deletion between exons 3 and 4 of the *C22ORF23* sequence (see fig. 3B and table 4 for corresponding primers). The whole deletion therefore encompasses 56–68 kb including, in addition to *SOX10*, *POLR2F* and part of *C22ORF23*.

In the case of patient 3, we performed FISH analysis, using RP5-1014D13 on one side and CTA-228A9 on the other. This allowed us to localize the centromeric border of the deletion between RP5-1014D13 (that shows hybridization on both chromosomes 22) and RP5-1039K5 (that shows only one signal on normal chromosome 22) (figs. 1C and 3A). The telomeric border was localized within CTA-228A9 (we observed a significantly decreased signal on one of the chromosomes 22 in all the metaphases) (fig. 3A). On the basis of these results, we repeated a series of multiplex PCR, using primers located within *C22ORF23* or *MICAL-L1* on one side and in *PLA2G6* on the other, and were able to finally determine the deletion boundaries between intron 9 and exon 8 of *MICAL-L1* and between exon 4 and intron 2 of *PLA2G6* (see fig. 3B and table 4 for corresponding primers). The whole deletion therefore encompasses 213–222 kb, including part of the *MICAL-L1* gene, the *C22ORF23*, *POLR2F*, *SOX10*, *PICK1*, *SLC16A8*, and *BAIAP2L2* genes, and part of the *PLA2G6* gene.

Identification of SOX10 Deletions in Patients with WS2

WS4-affected patients with *SOX10* point mutations or deletions exhibit a large variability and an incomplete penetrance of each feature (i.e., fully blue irides, patchy blue irides, or normal eyes; large, small, or no depigmented skin patches; short- or long-segment Hirschsprung disease or chronic intestinal pseudo-obstruction, etc.). Interestingly, we previously described a c.1076delGA mutation in a patient with a classic form of WS4¹⁸ that was inherited from a mother presenting with deafness and white forelock only. We also described a p.Ser135Thr (S135T) mutation in a patient presenting with a peculiar phenotype named “Yemenite deaf-blind hypopigmentation syndrome” without any intestinal dysfunction.⁴⁸ These two phenotypes, which are reminiscent of that observed in patients with WS2, prompted us to search for *SOX10* deletions in unexplained cases of WS2. Screening of 30 cases (previously found to be negative for *MITF*) by means of QMF-PCR allowed us to identify five different *SOX10* deletions (in patients 4–8) (see the “Subjects” section and table 1 for clinical descriptions).

The first encompasses exon 3 (fig. 4A, patient 4). PCR amplification with use of sets of primers located in exon 3 and intron 3, followed by cloning and sequencing of the PCR products, revealed a 253-bp deletion that removed 210 bp of exon 3 and 43 bp of intron 3 (fig. 4B). Interestingly, the patient’s brother, who presented with similar WS2 features, also carries the deletion (fig. 4B).




Figure 4. *SOX10* deletions in patients presenting with WS2. *A*, Schematic representation of the five deletions identified by QMF-PCR. The top scheme indicates the *SOX10* gene structure and QMF-PCR experiment results (+ = not deleted; - = deleted), as described in figure 1. *B* and *D*, Schematic representation (*top*) and electropherograms (*bottom*) of the breakpoint deletion region of patient 4 (*B*) and patient 5 (*D*) and their relatives. The sizes of the deletions and the breakpoints are indicated on the scheme. *C*, PCR covering exon 3 and intron-exon boundaries, with the use of DNA from patient 4, his brother, his mother, and his father, extracted from leukocytes (L), buccal cells (B), uroepithelial cells (U), and hair roots (H). The normal band is indicated by an arrow, and the mutant allele is indicated by an arrowhead. Note the faint mutant band in the mother's uroepithelial cells. *E*, Representative FISH result obtained for patient 8 with probe RP5-1039K5 encompassing the *SOX10* locus (indicated on the top scheme of panel A). The BAC clone RP5-1039K5 is shown in red, and the control probe (RP1-127L4) is shown in green. The normal chromosome 22 is indicated by an arrow, and the deleted chromosome 22 is indicated by an arrowhead.

use of the BAC clone RP5-1039K5 confirmed the presence of a deletion encompassing the whole region analyzed in patient 8 (fig. 4A and 4E). Analysis of the parents' samples revealed the de novo occurrence of the deletions in these three patients (table 1).

Molecular Characterization of Large Deletions in Patients Presenting with WS2

To define the boundaries of the three deletions encompassing the whole *SOX10* gene, we extended our analyses to adjacent regions. In the absence of material with which to perform FISH experiments in patients 6 and 7, we determined the boundaries of the deletion by repeating many sets of QMF-PCR (fig. 5B and data not shown). In the case of patient 6, additional sets of QMF-PCR primers between upstream S3 and S4 sequences allowed us to map the telomeric border of the deletion to a region located 20–21 kb upstream of the *SOX10* start codon. The centromeric border was localized between genes *CACNG2* and *MYH9*, therefore delimiting a deletion of 1.3–1.6 Mb that removes at least 42 genes, including *SOX10* and *TRIOBP* (fig. 5B).

Patient 7's deletion removes 574–898 kb. Indeed, boundaries were located between *LGALS2* and *SH3BP* on one side and *C22ORF5* and *KDELR3* on the other side. The deletion therefore encompasses 23 genes, including *SOX10*, *TRIOBP*, and *PLA2G6* (fig. 5B).

In the case of patient 8, FISH analysis was performed using several probes, including CTA-415G2, LL22NC01-95B1, RP1-288L1, CTA-714B7, RP5-1177I5, RP1-37E16, CTA-228A9, RP1-5O6, RP3-434P1, CTA-150C2, and RP4-742C19. The telomeric border was localized within the RP4-742C19 BAC (we observed a significantly decreased signal on one of the chromosomes 22 in all the metaphases) (fig. 5A), and the last centromeric deleted BAC was LL22NC01-95B1 (fig. 5B and data not shown). QMF-PCR with the use of primers within some of the genes located in the region confirmed the results, therefore delimiting a deletion of 5.5–6.1 Mb encompassing 102 different genes, including *SOX10*, *LARGE*, *RASD2*, *RBM9*, *MYH9*, *CACNG2*, *TRIOBP*, *PLA2G6*, *KCNJ4*, and *NPTXR* (fig. 5B and data not shown).

The identification of five *SOX10* deletions in the 30 cases studied revealed that *SOX10* is a new gene of WS2 and thus prompted us to screen for *SOX10* point mutations. However, we failed to detect any mutation by DNA sequencing of the three *SOX10* coding exons. Taken together, these results make *SOX10* the third gene discovered to be involved in WS2, with an estimated frequency (15%) similar to that of *MITF*.

Discussion

Considering our panel of patients presenting with WS4 (classic forms of WS4 and PCWH), we estimated that the phenotype is caused, for 20%–30% of patients, by *EDN3*

or *EDNRB* point mutations and, for 40%–50% of patients, by *SOX10* point mutations. In patients with WS2, mutations in the *MITF* gene were identified in ~15% of cases. Thus, 20%–40% of WS4 cases and 85% of WS2 cases remained unexplained at the molecular level, raising the possibility that other genes are involved or that some mutations within the known genes are not detected by the methods commonly used for genotyping. In this study, we describe the first characterization of *SOX10* deletions in patients presenting with WS4 and WS2. We found three deletions among 30 WS4 cases. Taking into account the fact that we tested only DNA samples of patients negative for *SOX10*, *EDN3*, and *EDNRB* point mutations, we estimate that *SOX10* deletions are involved in ~5% of all cases of WS4. We also found five deletions among 30 WS2 cases. Since we tested only patients negative for *MITF* mutations, we can estimate that *SOX10* deletions account for ~15% of all WS2 cases. These results extend the spectrum of *SOX10* mutations found in patients with WS4 and make *SOX10* the third gene discovered to be involved in WS2, with an estimated frequency similar to that of *MITF*. In terms of molecular diagnosis, *SOX10* deletions should now be searched for when no *SOX10* point mutations (PCWH) or no *SOX10*, *EDN3*, and *EDNRB* point mutations (classic form of WS4) are found. More importantly, *SOX10* deletions should be considered for first-step analysis in WS2, as well as *MITF* mutations.

Full characterization of the eight deletions by PCR and sequencing, or by a combination of QMF-PCR and FISH, revealed eight different deletion events ranging from the deletion of a single exon of *SOX10* to the deletion of up to 6 Mb around the *SOX10* locus (table 1). Both intragenic and full *SOX10* deletions were observed in either WS2 or WS4. Intragenic deletions involved different exons. The observation of sequences surrounding the breakpoints of the three intragenic deletions revealed no clear mechanism except for in patient 5, in whom the deletion occurred between two hexanucleotide repeats, tggggg, retaining one copy. Bioinformatics analysis with the use of Netgene2 and HMMgene software was performed to predict the functional consequences of these deletions. In the case of patient 1, the rearrangement was predicted to activate a cryptic splice-acceptor site within exon 5, located downstream of the stop codon (780 nt after the usual acceptor site; estimated frequency of 97%). The predicted protein would lack the last 206 aa and would be replaced by 27 unrelated aa, thereby removing the transactivation domain. In the case of patient 4, the deletion removed the exon 3–intron 3 boundary. *In silico* analysis revealed that this deletion could result in translation of a short intronic sequence with a nearby immediate stop codon (5 aa downstream), with the resulting protein devoid of all functional domains. Alternatively, the use of a cryptic splice-donor site (estimated frequency 55% or 88%, depending on the program used), located 55 nt downstream of the missing donor site, could produce a protein lacking 69 aa, removing the dimerization domain and half of the




Figure 5. Determination of the extent of large deletions in WS2. Schematic representation of the deletions in patients 6, 7, and 8 was determined by FISH (A) or QMF-PCR (B), as described in figure 3. Only the first nondeleted or partially deleted BACs are shown in panel A.

HMG domain but leaving the transactivation domain intact. In the case of patient 5, the Netgene2 software predicted that the deletion could lead to exon 4 skipping, therefore resulting in a frameshift and a truncated protein of 189 aa with 47 unrelated aa in the carboxyterminal part. Half of the HMG domain and the following domains would be removed. Unfortunately, there is no SOX10-expressing tissue easily accessible by noninvasive methods in patients, which precludes analysis of the protein produced in vivo.

Most of the *SOX10* disease-associated point mutations identified so far, regardless of whether they cause WS4 or PCWH, result in premature termination codons. An explanation for the presence or absence of a neurological phenotype (i.e., central or peripheral) that characterizes the PCWH syndrome has been hypothesized to be related to the NMD process.⁵⁷ Truncating mutations located in the first coding exons (exons 3 and 4) activate the NMD RNA surveillance pathway, leading to haploinsufficiency and classic forms of WS4. On the other hand, truncating mutations located in the last coding exon (exon 5) escape NMD, leading to translation of an abnormal SOX10 protein with a dominant negative effect and therefore resulting in the more severe PCWH phenotype. Considering the published^{18,47,49,50,52–58} and our unpublished cases with *SOX10* point mutations, we observed that the length of intestinal aganglionosis may also fit the NMD hypothesis, since all the point mutations associated with the long-segment Hirschsprung disease are located in exon 5. Accordingly, full deletions of *SOX10* would be expected to cause classic forms of WS4 with short-segment Hirschsprung disease as a result of haploinsufficiency. All three patients indeed present with a short form; however, two of them have mild PCWH syndrome, an observation that does not match the NMD hypothesis (table 1).

We wondered whether the PCWH syndrome might also result from other mechanisms, at least in some of the patients. Interestingly, one of the PCWH-affected patients with a *SOX10* deletion (patient 3) also carries a SOX10 valine→leucine substitution at the hemizygous state. This variation, which could worsen the phenotype of the patient, is located in a highly conserved region crucial for the mediation of DNA-dependent dimerization. We thus reasoned that the p.Val92Leu variation, although not a drastic substitution, might interfere with the formation of SOX10 dimers and thus specifically hamper promoter activation via natural target sites that require binding of SOX10 dimers. We therefore compared wild-type and p.Val92Leu SOX10 transactivation capacities on *MITF* and *GJB1* (Cx32) promoters containing monomeric or dimeric binding sites, respectively, and found no differences. These results suggest that the p.Val92Leu variation does not affect SOX10 function, at least in vitro, arguing in favor of the deletion as the major or sole cause of the PCWH phenotype observed. A contiguous gene syndrome may also account for the neurological features. The deletion identified in patient 3 encompasses the *PLA2G6*

gene known to be involved in a recessive neurological defect (infantile neuroaxonal dystrophy 1, neurodegeneration with brain iron accumulation, and Karak syndrome).⁶⁹ However, this gene is not deleted in patient 2, who has a mild PCWH syndrome resembling that of patient 3, suggesting that the heterozygous *PLA2G6* deletion is not involved in the phenotypic expression of the disease.

In WS2, as in WS4, the largest deletions are found in patients presenting with additional symptoms, suggesting that some features may be influenced by the presence of other genes. Indeed, several genes removed by one or more of the deletions have a well-established neurological role (i.e., *LARGE*, *RASD2*, *RBM9*, *CACNG2*, *KCNJ4*, and *NPTXR*). Two genes involved in human hearing loss are also located within some of the deleted regions: *TRIOBP* (recessive nonsyndromic deafness [DFNB28]⁷⁰) and *MYH9* (Epstein and Fechtner syndromes and dominant progressive isolated deafness [DFNA17]^{71,72}). However, when comparing all eight patients, we observed no clear correlation between the deletion of one of these genes and the presence of neurological features or the deafness phenotype. In fact, as for *SOX10* point mutations, *SOX10* deletions by themselves might be sufficient to explain the phenotypes observed. On the other hand, the autism of patient 7 and the cardiac defects of patient 8 have not previously been linked to *SOX10* mutations and may result from the deletion of additional genes. We found no evidence of a known gene removed by the deletion in patient 8, which could explain the cardiopathy, but this deletion encompasses 102 genes, and they are not all functionally characterized. In autism, recurrent deletions of chromosome 22q13 have been characterized,⁷³ including a frequent breakpoint within the *SHANK3* gene.⁷⁴ However, this region is distal to the deletion found in patient 7. The question of whether the association with autism in patient 7 is fortuitous or results from the deletion remains unanswered.

The WS subtypes were initially clinically defined. It appears, however, that this classification does not reflect the molecular mechanisms. Indeed, an overlap between WS1 and WS3 has already been reported, and we now report an overlap between WS2 and WS4. In developmental syndromes, incomplete penetrance of some features is commonly observed. Incomplete penetrance of Hirschsprung disease is described both in isolated and in syndromic forms of the disease, and it may result from different mechanisms, including genetic modifiers.^{75,76} In the case of WS, incomplete penetrance of Hirschsprung disease could explain the overlap between WS2 and WS4. However, with regard to this hypothesis, it is surprising to not find *SOX10* point mutations in WS2. To our knowledge, no genetic disorder has been described to result exclusively from deletions of the causative gene. It is possible that the penetrance of one feature varies between deletions and truncating point mutations, as shown, for example, in Von Hippel–Lindau disease.⁷⁷ In our case, in-

complete phenotypic penetrance may be explained by tissue-specific compensation of the loss of SOX10 by other SOX proteins having partly redundant function, such as SOX8 and SOX9. Interestingly, in mice that expressed SOX8 instead of SOX10, the enteric defect was partially or totally rescued in homozygotes or heterozygotes, respectively, whereas the pigmentation defect was not.⁷⁸ As a result, SOX10 haploinsufficiency may be compensated by SOX8 or SOX9 during enteric nervous-system development, explaining the low penetrance of Hirschsprung disease associated with *SOX10* deletions (leading to WS2 or WS4). In contrast, the presence of a truncated SOX10 protein may impair SOX8 or SOX9 function, resulting in a fully penetrant enteric phenotype (leading to WS4 only). However, it is possible that screening larger numbers of patients with WS2 will result in the identification of *SOX10* point mutations.

An increasing diversity of clinical features is reported in WS; some patients with WS4 present with pseudo-obstruction instead of Hirschsprung disease, and others present with myelination defects of the peripheral nervous system and CNS (i.e., PCWH syndrome). In this study, patients 7 and 8 presented with WS2 and central and peripheral neurological features typical of PCWH—formally, a new syndrome indicating a continuum from isolated WS2 to severe PCWH. On the basis of our observation of *SOX10* deletions in WS2, it appears possible that *EDN3* and *EDNRB* mutations also play a role in WS2. Indeed, in a subset of WS4-affected families with *EDN3* or *EDNRB* point mutations, heterozygous relatives present with a diversity of features that may occasionally recall WS2. It therefore appears necessary to undertake a more complete molecular analysis (including not only point mutations but also deletions) of all the genes involved in WS2 or WS4 (i.e., *MITF*, *EDN3*, and *EDNRB*). These comprehensive studies are necessary to fully document the molecular complexity and close relationship that link the different subtypes of WS and to reappraise their current clinical classification.

Acknowledgments

This work was supported by INSERM and Agence Nationale de la Recherche grant ANR-05-MRAR-008-01.

Web Resources

Accession numbers and URLs for data presented herein are as follows:

BACPAC Resources, <http://bacpac.chori.org/>
 GenBank, <http://www.ncbi.nlm.nih.gov/Genbank/> (for accession numbers NC_000021.7, NC_000023.9, and NC_000022.9)
 HMMgene, <http://www.cbs.dtu.dk/services/HMMgene/> (for gene-structure prediction)
 Netgene2, <http://www.cbs.dtu.dk/services/NetGene2/> (for neural-network predictions of splice sites in human DNA)
 Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/> (for WS1–WS4)

Wellcome Trust Sanger Institute, <http://www.sanger.ac.uk/>

References

1. Le Douarin NM, Kalcheim C (1999) The neural crest. Cambridge University Press, Cambridge, United Kingdom
2. Bolande RP (1974) The neurocristopathies: a unifying concept of disease arising in neural crest maldevelopment. *Hum Pathol* 5:409–429
3. Read AP, Newton VE (1997) Waardenburg syndrome. *J Med Genet* 34:656–665
4. Amiel J, Lyonnet S (2001) Hirschsprung disease, associated syndromes, and genetics: a review. *J Med Genet* 38:729–739
5. Waardenburg PJ (1951) A new syndrome combining developmental anomalies of the eyelids, eyebrows and nose root with pigmentary defects of the iris and head hair and with congenital deafness. *Am J Hum Genet* 3:195–253
6. Baldwin CT, Hoth CF, Amos JA, da-Silva EO, Milunsky A (1992) An exonic mutation in the *HuP2* paired domain gene causes Waardenburg's syndrome. *Nature* 355:637–638
7. Tassabehji M, Read AP, Newton VE, Harris R, Balling R, Gruss P, Strachan T (1992) Waardenburg's syndrome patients have mutations in the human homologue of the *Pax-3* paired box gene. *Nature* 355:635–636
8. Tassabehji M, Newton VE, Read AP (1994) Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (*MITF*) gene. *Nat Genet* 8:251–255
9. Sanchez-Martin M, Rodriguez-Garcia A, Perez-Losada J, Sagera A, Read AP, Sanchez-Garcia I (2002) *SLUG* (*SNAI2*) deletions in patients with Waardenburg disease. *Hum Mol Genet* 11:3231–3236
10. Shah KN, Dalal SJ, Desai MP, Sheth PN, Joshi NC, Ambani LM (1981) White forelock, pigmentary disorder of irides, and long segment Hirschsprung disease: possible variant of Waardenburg syndrome. *J Pediatr* 99:432–435
11. Puffenberger EG, Hosoda K, Washington SS, Nakao K, deWit D, Yanagisawa M, Chakravarti A (1994) A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. *Cell* 79:1257–1266
12. Chakravarti A (1996) Endothelin receptor-mediated signaling in Hirschsprung disease. *Hum Mol Genet* 5:303–307
13. Edery P, Attie T, Amiel J, Pelet A, Eng C, Hofstra RM, Martelli H, Bidaud C, Munnich A, Lyonnet S (1996) Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome). *Nat Genet* 12:442–444
14. Hofstra RM, Osinga J, Tan-Sindhunata G, Wu Y, Kamsteeg EJ, Stulp RP, van Ravenswaaij-Arts C, Majoor-Krakauer D, Angrist M, Chakravarti A, et al (1996) A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome). *Nat Genet* 12:445–447
15. McCallion AS, Chakravarti A (2001) *EDNRB/EDN3* and Hirschsprung disease type II. *Pigment Cell Res* 14:161–169
16. Pingault V, Bondurand N, Lemort N, Sancandi M, Ceccherini I, Hugot JP, Jouk PS, Goossens M (2001) A heterozygous endothelin 3 mutation in Waardenburg-Hirschsprung disease: is there a dosage effect of *EDN3/EDNRB* gene mutations on neurocristopathy phenotypes? *J Med Genet* 38:205–209
17. Brooks AS, Oostra BA, Hofstra RM (2005) Studying the genetics of Hirschsprung's disease: unraveling an oligogenic disorder. *Clin Genet* 67:6–14
18. Pingault V, Bondurand N, Kuhlbrodt K, Goerich DE, Prehu

- MO, Puliti A, Herbarth B, Hermans-Borgmeyer I, Legius E, Matthijs G, et al (1998) *SOX10* mutations in patients with Waardenburg-Hirschsprung disease. *Nat Genet* 18:171–173
19. Kapur RP (1999) Early death of neural crest cells is responsible for total enteric aganglionosis in Sox10(Dom)/Sox10(Dom) mouse embryos. *Pediatr Dev Pathol* 2:559–569
 20. Kim J, Lo L, Dormand E, Anderson DJ (2003) SOX10 maintains multipotency and inhibits neuronal differentiation of neural crest stem cells. *Neuron* 38:17–31
 21. Wegner M (1999) From head to toes: the multiple facets of Sox proteins. *Nucleic Acids Res* 27:1409–1420
 22. Mollaaghababa R, Pavan WJ (2003) The importance of having your SOX on: role of SOX10 in the development of neural crest-derived melanocytes and glia. *Oncogene* 22:3024–3034
 23. Hong CS, Saint-Jeannet JP (2005) Sox proteins and neural crest development. *Semin Cell Dev Biol* 16:694–703
 24. Wegner M, Stolt CC (2005) From stem cells to neurons and glia: a Soxist's view of neural development. *Trends Neurosci* 28:583–588
 25. Kelsh RN (2006) Sorting out Sox10 functions in neural crest development. *Bioessays* 28:788–798
 26. Foster JW, Dominguez-Steglich MA, Guioli S, Kowk G, Weller PA, Stevanovic M, Weissenbach J, Mansour S, Young ID, Goodfellow PN, et al (1994) Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-related gene. *Nature* 372:525–530
 27. Wagner T, Wirth J, Meyer J, Zabel B, Held M, Zimmer J, Pasantes J, Bricarelli FD, Keutel J, Hustert E, et al (1994) Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. *Cell* 79:1111–1120
 28. Bowles J, Schepers G, Koopman P (2000) Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. *Dev Biol* 227:239–255
 29. Peirano RI, Goerich DE, Riethmacher D, Wegner M (2000) Protein zero gene expression is regulated by the glial transcription factor Sox10. *Mol Cell Biol* 20:3198–3209
 30. Bondurand N, Pingault V, Goerich DE, Lemort N, Sock E, Caignec CL, Wegner M, Goossens M (2000) Interaction among *SOX10*, *PAX3* and *MITF*, three genes altered in Waardenburg syndrome. *Hum Mol Genet* 9:1907–1917
 31. Lang D, Chen F, Milewski R, Li J, Lu MM, Epstein JA (2000) Pax3 is required for enteric ganglia formation and functions with Sox10 to modulate expression of *c-ret*. *J Clin Invest* 106:963–971
 32. Lee M, Goodall J, Verastegui C, Ballotti R, Goding CR (2000) Direct regulation of the *microphthalmia* promoter by Sox10 links Waardenburg-Shah syndrome (WS4)-associated hypopigmentation and deafness to WS2. *J Biol Chem* 275:37978–37983
 33. Potterf SB, Fukumura M, Dunn KJ, Arnheiter H, Pavan WJ (2000) Transcription factor hierarchy in Waardenburg syndrome: regulation of MITF expression by SOX10 and PAX3. *Hum Genet* 107:1–6
 34. Verastegui C, Bille K, Ortonne JP, Ballotti R (2000) Regulation of the microphthalmia-associated transcription factor gene by the Waardenburg syndrome type 4 gene, *SOX10*. *J Biol Chem* 275:30757–30760
 35. Elworthy S, Lister JA, Carney TJ, Raible DW, Kelsh RN (2003) Transcriptional regulation of *mitfa* accounts for the sox10 requirement in zebrafish melanophore development. *Development* 130:2809–2818
 36. Jiao Z, Mollaaghababa R, Pavan WJ, Antonellis A, Green ED, Hornyak TJ (2004) Direct interaction of Sox10 with the promoter of murine *Dopachrome Tautomerase (Dct)* and synergistic activation of *Dct* expression with Mitf. *Pigment Cell Res* 17:352–362
 37. Ludwig A, Rehberg S, Wegner M (2004) Melanocyte-specific expression of dopachrome tautomerase is dependent on synergistic gene activation by the Sox10 and Mitf transcription factors. *FEBS Lett* 556:236–244
 38. Zhu L, Lee HO, Jordan CS, Cantrell VA, Southard-Smith EM, Shin MK (2004) Spatiotemporal regulation of endothelin receptor-B by SOX10 in neural crest-derived enteric neuron precursors. *Nat Genet* 36:732–737
 39. Wegner M (2005) Secrets to a healthy Sox life: lessons for melanocytes. *Pigment Cell Res* 18:74–85
 40. Yokoyama S, Takeda K, Shibahara S (2006) SOX10, in combination with Sp1, regulates the *endothelin receptor type B* gene in human melanocyte lineage cells. *FEBS J* 273:1805–1820
 41. Murisier F, Guichard S, Beermann F (2007) The tyrosinase enhancer is activated by Sox10 and Mitf in mouse melanocytes. *Pigment Cell Res* 20:173–184
 42. Peirano RI, Wegner M (2000) The glial transcription factor Sox10 binds to DNA both as monomer and dimer with different functional consequences. *Nucleic Acids Res* 28:3047–3055
 43. Bondurand N, Girard M, Pingault V, Lemort N, Dubourg O, Goossens M (2001) Human connexin 32, a gap junction protein altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by the transcription factor SOX10. *Hum Mol Genet* 10:2783–2795
 44. Britsch S, Goerich DE, Riethmacher D, Peirano RI, Rossner M, Nave KA, Birchmeier C, Wegner M (2001) The transcription factor Sox10 is a key regulator of peripheral glial development. *Genes Dev* 15:66–78
 45. Schlierf B, Ludwig A, Klenovsek K, Wegner M (2002) Cooperative binding of Sox10 to DNA: requirements and consequences. *Nucleic Acids Res* 30:5509–5516
 46. Stolt CC, Rehberg S, Ader M, Lommes P, Riethmacher D, Schachner M, Bartsch U, Wegner M (2002) Terminal differentiation of myelin-forming oligodendrocytes depends on the transcription factor Sox10. *Genes Dev* 16:165–170
 47. Touraine RL, Attie-Bitach T, Pelet A, Auge J, Pingault V, Amiel J, Goossens M, Delezoide AL, Razavi F, Munnich A, et al (1998) Expression of SOX10 in human embryo and fetal brain accounts for a neurological phenotype in Waardenburg type 4 spectrum. *Am J Hum Genet* 63:A174
 48. Bondurand N, Kuhlbrodt K, Pingault V, Enderich J, Sajus M, Tommerup N, Warburg M, Hennekam RC, Read AP, Wegner M, et al (1999) A molecular analysis of the Yemenite deaf-blind hypopigmentation syndrome: SOX10 dysfunction causes different neurocristopathies. *Hum Mol Genet* 8:1785–1789
 49. Inoue K, Tanabe Y, Lupski JR (1999) Myelin deficiencies in both the central and the peripheral nervous systems associated with a *SOX10* mutation. *Ann Neurol* 46:313–318
 50. Southard-Smith EM, Angrist M, Ellison JS, Agarwala R, Baxevanis AD, Chakravarti A, Pavan WJ (1999) The *Sox10^{Dom}* mouse: modeling the genetic variation of Waardenburg-Shah (WS4) syndrome. *Genome Res* 9:215–225
 51. Pingault V, Guiochon-Mantel A, Bondurand N, Faure C, Lacroix C, Lyonnet S, Goossens M, Landrieu P (2000) Peripheral neuropathy with hypomyelination, chronic intestinal pseudo-

- obstruction and deafness: a developmental “neural crest syndrome” related to a *SOX10* mutation. *Ann Neurol* 48:671–676
52. Touraine RL, Attie-Bitach T, Manceau E, Korsch E, Sarda P, Pingault V, Encha-Razavi F, Pelet A, Auge J, Nivelon-Chevallier A, et al (2000) Neurological phenotype in Waardenburg syndrome type 4 correlates with novel *SOX10* truncating mutations and expression in developing brain. *Am J Hum Genet* 66:1496–1503
 53. Sham MH, Lui VC, Chen BL, Fu M, Tam PK (2001) Novel mutations of *SOX10* suggest a dominant negative role in Waardenburg-Shah syndrome. *J Med Genet* 38:E30
 54. Inoue K, Shilo K, Boerkoel CF, Crowe C, Sawady J, Lupski JR, Agamanolis DP (2002) Congenital hypomyelinating neuropathy, central dysmyelination, and Waardenburg-Hirschsprung disease: phenotypes linked by *SOX10* mutation. *Ann Neurol* 52:836–842
 55. Pingault V, Girard M, Bondurand N, Dorkins H, Van Maldergem L, Mowat D, Shimotake T, Verma I, Baumann C, Goossens M (2002) *SOX10* mutations in chronic intestinal pseudo-obstruction suggest a complex physiopathological mechanism. *Hum Genet* 111:198–206
 56. Toki F, Suzuki N, Inoue K, Suzuki M, Hirakata K, Nagai K, Kuroiwa M, Lupski JR, Tsuchida Y (2003) Intestinal aganglionosis associated with the Waardenburg syndrome: report of two cases and review of the literature. *Pediatr Surg Int* 19:725–728
 57. Inoue K, Khajavi M, Ohyama T, Hirabayashi S, Wilson J, Reggin JD, Mancias P, Butler JJ, Wilkinson MF, Wegner M, et al (2004) Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. *Nat Genet* 36:361–369
 58. Verheij JB, Sival DA, van der Hoeven JH, Vos YJ, Meiners LC, Brouwer OF, van Essen AJ (2006) Shah-Waardenburg syndrome and PCWH associated with *SOX10* mutations: a case report and review of the literature. *Eur J Paediatr Neurol* 10:11–17
 59. Niel F, Martin J, Dastot-Le Moal F, Costes B, Boissier B, Delattre V, Goossens M, Girodon E (2004) Rapid detection of *CFTR* gene rearrangements impacts on genetic counselling in cystic fibrosis. *J Med Genet* 41:e118
 60. Dastot-Le Moal F, Wilson M, Mowat D, Collot N, Niel F, Goossens M (2007) *ZFX1B* mutations in patients with Mowat-Wilson syndrome. *Hum Mutat* 28:313–321
 61. Yau SC, Bobrow M, Mathew CG, Abbs SJ (1996) Accurate diagnosis of carriers of deletions and duplications in Duchenne/Becker muscular dystrophy by fluorescent dosage analysis. *J Med Genet* 33:550–558
 62. Pinkel D, Straume T, Gray JW (1986) Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. *Proc Natl Acad Sci USA* 83:2934–2938
 63. Girard M, Goossens M (2006) Sumoylation of the *SOX10* transcription factor regulates its transcriptional activity. *FEBS Lett* 580:1635–1641
 64. Maka M, Stolt CC, Wegner M (2005) Identification of *Sox8* as a modifier gene in a mouse model of Hirschsprung disease reveals underlying molecular defect. *Dev Biol* 277:155–169
 65. Antonellis A, Bennett WR, Menhenniott TR, Prasad AB, Lee-Lin SQ, Green ED, Paisley D, Kelsh RN, Pavan WJ, Ward A (2006) Deletion of long-range sequences at *Sox10* compromises developmental expression in a mouse model of Waardenburg-Shah (WS4) syndrome. *Hum Mol Genet* 15:259–271
 66. Sock E, Pagon RA, Keymolen K, Lissens W, Wegner M, Scherer G (2003) Loss of DNA-dependent dimerization of the transcription factor *SOX9* as a cause for campomelic dysplasia. *Hum Mol Genet* 12:1439–1447
 67. Houlden H, Girard M, Cockerell C, Ingram D, Wood NW, Goossens M, Walker RW, Reilly MM (2004) *Connexin 32* promoter P2 mutations: a mechanism of peripheral nerve dysfunction. *Ann Neurol* 56:730–734
 68. Lang D, Epstein JA (2003) *Sox10* and *Pax3* physically interact to mediate activation of a conserved *c-RET* enhancer. *Hum Mol Genet* 12:937–945
 69. Morgan NV, Westaway SK, Morton JE, Gregory A, Gissen P, Sonek S, Cangul H, Coryell J, Canham N, Nardocci N, et al (2006) *PLA2G6*, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. *Nat Genet* 38:752–754
 70. Shahin H, Walsh T, Sobe T, Abu Sa’ed J, Abu Rayan A, Lynch ED, Lee MK, Avraham KB, King MC, Kanaan M (2006) Mutations in a novel isoform of *TRIOBP* that encodes a filamentous-actin binding protein are responsible for DFNB28 recessive nonsyndromic hearing loss. *Am J Hum Genet* 78:144–152
 71. Lalwani AK, Goldstein JA, Kelley MJ, Luxford W, Castelein CM, Mhatre AN (2000) Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin *MYH9*. *Am J Hum Genet* 67:1121–1128
 72. Heath KE, Campos-Barros A, Toren A, Rozenfeld-Granot G, Carlsson LE, Savige J, Denison JC, Gregory MC, White JG, Barker DF, et al (2001) Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. *Am J Hum Genet* 69:1033–1045
 73. Phelan MC, Rogers RC, Saul RA, Stapleton GA, Sweet K, McDermid H, Shaw SR, Clayton J, Willis J, Kelly DP (2001) 22q13 deletion syndrome. *Am J Med Genet* 101:91–99
 74. Bonaglia MC, Giorda R, Mani E, Aceti G, Anderlid BM, Baroncini A, Pramparo T, Zuffardi O (2006) Identification of a recurrent breakpoint within the *SHANK3* gene in the 22q13.3 deletion syndrome. *J Med Genet* 43:822–828
 75. Attie T, Pelet A, Edery P, Eng C, Mulligan LM, Amiel J, Boutrand L, Beldjord C, Nihoul-Fekete C, Munnich A, et al (1995) Diversity of *RET* proto-oncogene mutations in familial and sporadic Hirschsprung disease. *Hum Mol Genet* 4:1381–1386
 76. de Pontual L, Pelet A, Clement-Ziza M, Trochet D, Antonarakis SE, Attie-Bitach T, Beales PL, Blouin JL, Dastot-Le Moal F, Dollfus H, et al (2007) Epistatic interactions with a common hypomorphic *RET* allele in syndromic Hirschsprung disease. *Hum Mutat* 28:790–796
 77. Wong WT, Agron E, Coleman HR, Reed GF, Csaky K, Peterson J, Glenn G, Linehan WM, Albert P, Chew EY (2007) Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomas. *Arch Ophthalmol* 125:239–245
 78. Kellerer S, Schreiner S, Stolt CC, Scholz S, Bosl MR, Wegner M (2006) Replacement of the *Sox10* transcription factor by *Sox8* reveals incomplete functional equivalence. *Development* 133:2875–2886